Taibang Biological Group Co., Ltd.

Founded in 2002, Taibang Biologic Group (“Taibang”) is a leading Chinese biopharmaceutical company that provides a comprehensive range of plasma-derived products. The company's core business includes the development, manufacture and sale of plasma-derived products and other biopharmaceutical products.

As a leader in China's plasma-derived products industry, Taibang possesses leading international technology, one of the largest manufacturing capacities for plasma-derived products in Asia, and world-class R&D capabilities. The company's industry-leading product portfolio currently includes 10 plasma-derived products covering more than 20 specifications in three main categories: human albumin, human immunoglobulin, and human coagulation factors.

Taibang's non-plasma-derived products business segment covers a wide range of products including artificial dura, artificial spinal dura, artificial nerve conduits and anti-adhesion membranes for tendons.

In 2009, Taibang was listed on the Nasdaq Stock Exchange under the trading symbol “CBPO”. Over the course of its many years in operation, Taibang has become an industry-leading, international biopharmaceutical company. In April 2021, Taibang successfully completed its approximately $4.8 billion privatization with the support of several well-known investment funds.

With its mission to produce quality medicines that benefit humanity and its commitment to excellence and innovation, Taibang is focused on leveraging the latest R&D to manufacture top-notch products that set the standard for quality, safety and effectiveness.

Shandong Manufacturing Base

No.5666, Longquan Road, Hi-Tech Zone, Tai'an City, Shandong Province,China

Guizhou Manufacturing Base

No.156, Daqian Road, Huaxi District, Guiyang City, Guizhou Province,China

Medical Device Manufacturing Base

No.30, Huoju Street, Science Park, Changping District, Beijing,China